Artificial Intelligence, Medical Research and Neurodegenerative Disease

ACCELERATING THE SEARCH FOR NEW TREATMENTS FOR DISEASES LIKE ALZHEIMER'S AND PARKINSON'S

Brown alumnus and researcher John Crary, MD-PhD '96, presents his research applying artificial intelligence to the study of neurodegenerative diseases and offers a "mini tour" of his research lab!

Join us for a special presentation, showcasing the groundbreaking work of John Crary, '96. Dr. Crary is applying artificial intelligence (machine learning)-based approaches, including computer vision, to understand neurodegenerative disease and develop new, more effective diagnostics and treatments. Join us for a "mini lab tour" led by Dr. Crary's research team and featuring resources from his lab, which will take place before and after the program.

Dr. Crary's research focuses on understanding the molecular changes that occur in neurodegenerative diseases, including dementias, such as Alzheimer's disease, movement disorders, such as Parkinson’s disease and related conditions, and the long-term consequences of repetitive traumatic brain injury. Dr. Crary leads the Mount Sinai Neuropathology Brain Bank which serves as a resource for neuroscience researchers around the world.

John Crary, MD-PhD '96 is an experimental neurobiologist and board-certified neuropathologist. Dr. Crary has made substantial contributions to the way human brain diseases are diagnosed through an international network of neuropathologists, defining numerous neuropathological diagnostic categories. He spearheaded an international effort to establish consensus criteria for primary age-related tauopathy (PART). He has also contributed to efforts to define consensus criteria for aging-related tau astrogliopathy, chronic traumatic encephalopathy, and progressive supranuclear palsy. He is pioneering computer vision approaches (e.g., deep machine learning) to modernize histopathological evaluation of brain tissues. Further, he leads independent basic studies probing fundamental mechanisms of neurodegeneration, mechanistically characterizing these changes with animal and cellular models, with a goal of bringing these insights back to clinical practice. Notably, he has led and contributed to numerous genetic and cellular studies examining toxicity and regulation of expression of tau using novel animal and stem-cell-derived models. For more information about the Crary lab at Mount Sinai Hospital, please view his Website: crarylab.org

Questions? Email: tonypillari@brownnyc.org